Core Viewpoint - 瑞康医药 has completed its share repurchase plan, acquiring a total of 34,638,659 shares, which represents 2.31% of the company's total share capital [1] Summary by Categories Share Repurchase Details - The company repurchased shares through a centralized bidding transaction method, with a total payment amounting to RMB 101,475,367.91 (excluding transaction fees) [1] - The highest transaction price was 3.08 RMB per share, while the lowest was 2.75 RMB per share [1] - The repurchase period spanned from February 14, 2025, to November 6, 2025 [1] Compliance and Implementation - The total amount spent on the repurchase has reached the lower limit of the planned repurchase funds and has not exceeded the upper limit [1] - The repurchase prices did not exceed the upper limit set in the repurchase plan [1] - The repurchase complies with relevant laws and regulations and aligns with the established share repurchase plan [1]

证券代码：002589 证券简称：瑞康医药 公告编号：2025-053 瑞康医药集团股份有限公司 关于回购结果暨股份变动的公告 瑞康医药集团股份有限公司（以下简称"公司"）于 2024 年 11 月 7 日召开 第五届董事会第十次会议，审议通过了《关于回购公司股份方案的议案》。该议 案同意公司使用银行专项贷款资金及自有资金以集中竞价交易方式回购公司部 分已发行的人民币普通股（A 股），用于股权激励或实施员工持股计划。本次回 购资金总额不低于人民币 10,000 万元（含）且不超过人民币 20,000 万元（含）， 回购价格不超过人民币 4.50 元/股。具体回购股份的数量以回购期满时实际回购 的股份数量为准。回购期限自董事会审议通过本次回购股份方案之日起不超过十 二个月。具体内容详见公司于 2024 年 11 月 11 日、2024 年 12 月 12 日等在巨潮 资讯网上披露的相关公告。 截至本公告日，公司本次回购股份实施期限已经届满，公司已按披露的回购 方案完成回购。根据《上市公司股份回购规则（2025 年修订）》和《深圳证券 交易所上市公司自律监管指引第 9 号—回购股份（2025 年修订）》等相关法律 ...

Core Viewpoint - Ruikang Pharmaceutical has completed its share repurchase plan as of November 6, with a total of 34,638,659 shares repurchased, accounting for 2.31% of the company's total share capital [1] Summary by Relevant Sections - **Share Repurchase Details** - The repurchase was conducted through centralized bidding transactions [1] - The highest transaction price was 3.08 CNY per share, while the lowest was 2.75 CNY per share [1] - The total amount paid for the repurchase was 101 million CNY [1] - **Purpose of Repurchased Shares** - The repurchased shares will be used for equity incentives or to implement an employee stock ownership plan [1] - If the shares are not utilized for these purposes within 36 months, the unused portion will be legally canceled [1] - **Financial Impact** - The share repurchase is not expected to have a significant impact on the company's financials [1] - During the implementation period, relevant parties did not engage in buying or selling the company's stock [1]

Core Viewpoint - Ruikang Pharmaceutical (002589) announced the repurchase of 30,504,859 shares, representing 2.03% of the company's total share capital, through a centralized bidding trading method as of November 4, 2025 [1] Summary by Category - **Company Actions** - The company has initiated a share repurchase program, accumulating a total of 30,504,859 shares [1] - The repurchased shares account for 2.03% of the current total share capital of the company [1]

Core Viewpoint - Ruikang Pharmaceutical (002589.SZ) has repurchased a total of 30.5049 million shares, representing 2.03% of the company's total share capital, with a total transaction amount of 89.2961 million yuan [1] Summary by Category - **Share Repurchase Details** - The company has conducted share repurchases through a special securities account via centralized bidding [1] - The highest transaction price was 3.08 yuan per share, while the lowest was 2.75 yuan per share [1] - The total amount spent on the repurchase, excluding transaction fees, is 89.2961 million yuan [1]

证券代码：002589 证券简称：瑞康医药 公告编号：2025-052 1 瑞康医药集团股份有限公司 关于回购公司股份比例达到 2 %暨回购进展的公告 瑞康医药集团股份有限公司（以下简称"公司"、"瑞康医药"）于 2024 年 11 月 7 日召开第五届董事会第十次会议，审议通过了《关于回购公司股份方 案的议案》，同意公司使用银行专项贷款资金及自有资金以集中竞价交易方式回 购公司部分已发行的人民币普通股（A 股），本次回购股份将用于实施员工持 股计划，回购股份的资金总额不低于人民币 10,000 万元（含），不超过人民币 20,000 万元（含），回购股份的价格不超过人民币 4.5 元/股（含），具体回购 股份的数量以回购期限届满或回购完毕时实际回购的股份数量为准，实施期限为 董事会审议通过回购股份方案之日起 12 个月内。具体内容详见公司于 2024 年 11 月 11 日在巨潮资讯网披露《第五届董事会第十次会议决议的公告》（2024-036） 及《关于回购公司股份方案暨取得金融机构股票回购专项贷款承诺函的公告》（公 告编号：2024-037）、2024 年 12 月 12 日在巨潮资讯网披露《回购报告书》 ...

Core Viewpoint - The company announced a share buyback plan, intending to repurchase 27,826,259 shares, which represents 1.85% of its total share capital, with a total transaction amount of 81.4746 million yuan [1] Summary by Categories - **Share Buyback Details** - The company will repurchase shares through a dedicated securities account via centralized bidding [1] - The maximum transaction price is set at 3.08 yuan per share, while the minimum price is 2.75 yuan per share [1] - The total amount for the share buyback is 81.4746 million yuan, excluding transaction fees [1] - **Compliance and Regulations** - The share buyback aligns with the company's established repurchase plan and complies with relevant laws and regulations [1]

证券代码：002589 证券简称：瑞康医药 公告编号：2025-051 瑞康医药集团股份有限公司 公司回购股份的时间、回购股份数量、回购股份价格及集中竞价交易的委托 时段符合《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》的相关 规定。具体如下： （一）公司未在下列期间内以集中竞价交易方式回购股份： 关于回购公司股份的进展公告 瑞康医药集团股份有限公司（以下简称"公司"、"瑞康医药"）于 2024 年 11 月 7 日召开第五届董事会第十次会议，审议通过了《关于回购公司股份方 案的议案》，同意公司使用银行专项贷款资金及自有资金以集中竞价交易方式回 购公司部分已发行的人民币普通股（A 股），本次回购股份将用于实施员工持股 计划，回购股份的资金总额不低于人民币 10,000 万元（含），不超过人民币 20,000 万元（含），回购股份的价格不超过人民币 4.5 元/股（含），具体回购股份的数 量以回购期限届满或回购完毕时实际回购的股份数量为准，实施期限为董事会审 议通过回购股份方案之日起 12 个月内。具体内容详见公司于 2024 年 11 月 11 日 在巨潮资讯网披露《第五届董事会第十次会议决议的 ...

2025年1至6月份，瑞康医药的营业收入构成为：药品及器械销售占比98.42%，移动医疗占比0.67%，其 他占比0.6%，租赁占比0.31%。 （记者 王晓波） 每经头条（nbdtoutiao）——中国这个行业爆了！海外订单猛增246%，覆盖50多国和地区，企业家提 醒：有人正以亏本价销售，警惕恶性竞争扩至海外 每经AI快讯，瑞康医药（SZ 002589，收盘价：2.93元）11月4日晚间发布公告称，截至2025年10月31 日，公司通过股份回购专用证券账户以集中竞价方式回购公司股份约2782.63万股，占公司目前总股本 的1.85%，最高成交价3.08元/股，最低成交价2.75元/股，成交总金额8147.46万元。 截至发稿，瑞康医药市值为44亿元。 ...

Core Viewpoint - The financial report of Ruikang Pharmaceutical for Q3 2025 highlights the company's ongoing operational difficulties, with significant declines in revenue and net profit, despite some improvements in non-recurring profit metrics and cash flow [1][9]. Financial Performance - Total revenue for the first three quarters was 5.407 billion yuan, a year-on-year decrease of 10.73% [1][2]. - Net profit attributable to shareholders was 12.14 million yuan, down 63.05% compared to the same period last year [1][2]. - The adjusted net profit (excluding non-recurring items) showed a significant increase of 184.63%, reaching 6.587 million yuan [1][2]. - Operating cash flow net amount was 40.576 million yuan, an increase of 244.72% year-on-year [1][2]. Industry Context - The pharmaceutical distribution industry is undergoing structural changes, with the market size reaching 29,580 billion yuan in 2023, but dominated by leading companies like China National Pharmaceutical Group and Shanghai Pharmaceuticals, which hold 42.32% of the market share [4][5]. - Ruikang Pharmaceutical's market position is declining, with a total market value of 4.364 billion yuan, ranking 17th in the pharmaceutical distribution sector [5]. Strategic Initiatives - The company is focusing on a dual strategy of "distribution business + traditional Chinese medicine innovation" to drive growth [6]. - Ruikang has established a planting network for traditional Chinese medicine and is investing in microbiome technology through a joint venture [6]. - The acquisition of a 76.01% stake in Zhejiang Hengjiu for 151 million yuan aims to enter the breast cancer diagnostic equipment market, despite the target company having zero revenue and losses prior to the acquisition [6]. Management Challenges - The company is facing internal management turmoil, with the recent detention of a key executive raising compliance concerns [7][8]. - The resignation of another core management member adds to the instability, which could impact the company's strategic transformation efforts [7][8]. Profitability Concerns - The net profit margin for the first three quarters of 2025 was only 0.50%, down from 0.86% in the same period last year, indicating ongoing challenges in achieving sustainable profitability [9]. - The company has struggled with non-recurring profits supporting its financial results, while core business operations have not yet established a stable profit model [9].